Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Capital Expenditures (2016 - 2025)

Cytosorbents' Capital Expenditures history spans 15 years, with the latest figure at $108000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $108000.0 for Q4 2025, up 152.17% from a year ago — trailing twelve months through Dec 2025 was $164000.0 (up 1950.0% YoY), and the annual figure for FY2025 was $164000.0, up 1950.0%.
  • Capital Expenditures for Q4 2025 was $108000.0 at Cytosorbents, up from $17000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.6 million in Q4 2021 to a low of -$480415.0 in Q2 2022.
  • The 5-year median for Capital Expenditures is $50905.0 (2022), against an average of $247964.6.
  • Peak annual rise in Capital Expenditures hit 2147.6% in 2021, while the deepest fall reached 629.44% in 2021.
  • Year by year, Capital Expenditures stood at $3.6 million in 2021, then plummeted by 97.82% to $79236.0 in 2022, then grew by 20.52% to $95497.0 in 2023, then crashed by 316.76% to -$207000.0 in 2024, then surged by 152.17% to $108000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $108000.0, $17000.0, and $36879.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.